Summary & Overview
HCPCS C9083: Injection, amivantamab-vmjw, 10 mg
HCPCS Level II code C9083 bills for injections of amivantamab-vmjw dosed per 10 mg units, a targeted monoclonal antibody used in oncology. Nationally, accurate coding for specialized injectable therapies matters for appropriate patient access, formulary management, and consistent claims processing across payers. This code identifies the specific drug product distinct from administration-only codes and supports drug cost reporting on the claim line. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise primer on the clinical and billing context for C9083, benchmarks for payer coverage and reimbursement practices, common modifier usage, and practical considerations for claim submission and site-of-service designation. The publication also outlines where to find related HCPCS and administration codes and how billing workflows typically accommodate high-cost injectable oncology therapies. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9083 represents Injection, amivantamab-vmjw, 10 mg. This code describes a parenteral pharmaceutical product administered as an injection. Service type: Drug administration (injectable oncologic/targeted therapy). Typical site of service: outpatient infusion center or hospital outpatient department, depending on clinical setting and payer rules.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced or metastatic non–small cell lung cancer harboring an EGFR exon 20 insertion mutation who is prescribed targeted intravenous therapy with C9083 (amivantamab-vmjw, 10 mg). The medication is prepared by pharmacy in an oncology infusion center and administered by an oncology nurse. Workflow steps: referral and authorization, baseline assessment (vital signs, weight, allergy review), review of recent imaging and labs (CBC, CMP), calculation of dose based on body weight per drug labeling, premedication as required (antihistamine, acetaminophen, corticosteroid for infusion reactions), placement of peripheral IV or use of existing central venous access, infusion under direct nursing observation with vital sign monitoring at regular intervals, recognition and management of infusion-related reactions, documentation of lot number and administered amount, and post-infusion observation for delayed reactions. Typical sites of service are hospital outpatient oncology infusion centers, physician office infusion suites, and ambulatory infusion centers. Common modifiers applied depend on clinical circumstances such as unusual procedural services, reduced services, patient status, or provider role during the infusion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work, time, or complexity of the infusion is substantially greater than typical (for example, prolonged infusion due to severe infusion reaction management). |